Convalescent plasma, donated by COVID-19 recovered persons is a cellular component of blood that contains isotope specific antibodies such as IgA, IgG and IgM. Plasma therapy consists of transfusion of convalescent plasma to the COVID patients. The present investigation was a single center, non-randomized, comparative study to evaluate efficacy and safety of convalescent plasma therapy as an add on therapy to standard of care in moderate COVID-19 patients. A total of 135 patients received convalescent plasma and results showed no significant statistical difference in the outcome of the patients who received plasma therapy when compared with the patients who did not received plasma therapy. Therefore the study concludes that convalescent plasma therapy was not supportive to the standard of care in improving the health of COVID-19 patients with bronchopneumonia.